Piper Sandler Maintains Neutral on NovoCure, Lowers Price Target to $62
Portfolio Pulse from richadhand@benzinga.com
Piper Sandler analyst Jason Bednar maintains a Neutral rating on NovoCure (NASDAQ:NVCR) and lowers the price target from $67 to $62.
June 07, 2023 | 2:14 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Piper Sandler analyst maintains a Neutral rating on NovoCure and lowers the price target from $67 to $62.
The news directly mentions NovoCure (NASDAQ:NVCR) and the lowered price target by Piper Sandler analyst Jason Bednar. The Neutral rating is maintained, indicating no significant change in the stock's outlook. However, the lowered price target may cause some investors to reevaluate their positions, but the overall impact on the stock price in the short term is expected to be neutral.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100